Save the date for Swedish Orphan Biovitrum AB (publ) (Sobi™) Capital Markets Day on 14 May 2019. The event will take place at Karolinska Institutet Biomedicum, Solnavägen 9, Solna, from 12:30 – 16:30. A lighter lunch will be served at 11:30. We also welcome all participants to a lab safari, taking place at Sobi’s premises at Tomtebodavägen 23A, close to Biomedicum, from 10:30-11:30. Let us know if you wish to participate in the lab safari when you register to the event.
The Capital Markets Day will be an opportunity for institutional investors, analysts and media to learn more about Sobi, our therapeutic areas and future growth strategy as well our financial performance.
The agenda and more detailed information about the event will be published on Sobi’s website closer to the event.
Please register at [email protected] by the latest on 12 April.
Name, company, e-mail address, phone number, participation in the lab safari, participation in the lunch as well as food allergies, if any.
We look forward to seeing you in May.
Welcome!
For more information, please contact:
Paula Treutiger, Head of Communications and IR
+ 46 733 666 599
[email protected]
Linda Holmström, Senior Communications/IR Manager
+46 708 734 095
[email protected]
About Sobi™
At Sobi, we are transforming the lives of people affected by rare diseases. As a specialised international biopharmaceutical company, we provide sustainable access to innovative therapies in the areas of haematology, immunology and specialty care. We bring something rare to rare diseases – a belief in the strength of focus, the power of agility and the potential of the people we are dedicated to serving. The hard work and dedication of our approximately 1050 employees around the globe has been instrumental in our success across Europe, North America, the Middle East, Russia and North Africa, leading to total revenues of SEK 9.1 billion in 2018. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at www.sobi.com.
Swedish Orphan Biovitrum AB (publ)
Postal address SE-112 76 Stockholm, Sweden
Phone: 46 8 697 20 00 www.sobi.com
We are a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases.
Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care.
We contribute to societies by improving access to treatment of rare diseases.
Find out more about our business and financial performance.
Here we present our most recent press releases, news articles, and images.
Every day, we work actively to find better ways to understand and meet patient needs.